{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:38:34Z","timestamp":1790807914588,"version":"4.1.0"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02329","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:40:50Z","timestamp":1539564050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":61,"title":["Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN"],"prefix":"10.3389","volume":"9","author":[{"given":"Roberta","family":"Donadelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pulieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevas","family":"Iatropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Valoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Noris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semnephrol.2011.06.005","article-title":"Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification","volume":"31","author":"Sethi","year":"2011","journal-title":"Semin Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00467-009-1322-7","article-title":"Membranoproliferative glomerulonephritis","volume":"25","author":"Alchi","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1084\/jem.131.6.1306","article-title":"Characteristics of a non-complement-dependent C3-reactive complex formed form factors in nephritic and normal serum","volume":"131","author":"Vallota","year":"1970","journal-title":"J Exp Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI105555","article-title":"Evidence for in vivo breakdown of beta-10-globulin in hypocomplementemic glomerulonephritis","volume":"46","author":"West","year":"1967","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0090-1229(78)90160-5","article-title":"Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN)","volume":"10","author":"Levy","year":"1978","journal-title":"Clin Immunol Immunopathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1681\/ASN.2005010078","article-title":"Membranoproliferative glomerulonephritis type II (dense deposit disease): an update","volume":"16","author":"Appel","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00433081","article-title":"Basement membrane changes in membranoproliferative glomerulonephritis. II. Characterization of a third type by silver impregnation of ultra thin sections","volume":"376","author":"Anders","year":"1977","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2013a new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrneph.2014.217","article-title":"Histopathology of MPGN and C3 glomerulopathies","volume":"11","author":"Cook","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/ki.2013.340","article-title":"Toward a working definition of C3 glomerulopathy by immunofluorescence","volume":"85","author":"Hou","year":"2014","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1093\/ndt\/gfs288","article-title":"Idiopathic membranoproliferative glomerulonephritis: does it exist?","volume":"27","author":"Fervenza","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/j.humpath.2014.07.021","article-title":"Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up","volume":"45","author":"Figueres","year":"2014","journal-title":"Hum Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex-mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.164.3878.436","article-title":"Serum C'3 lytic system in patients with glomerulonephritis","volume":"164","author":"Spitzer","year":"1969","journal-title":"Science"},{"key":"B18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4049\/jimmunol.123.2.755","article-title":"Further evidence for the antibody nature of C3 nephritic factor (C3NeF)","volume":"123","author":"Daha","year":"1979","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","article-title":"The role of complement in C3 glomerulopathy","volume":"67","author":"Zipfel","year":"2015","journal-title":"Mol Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1073\/pnas.74.9.3980","article-title":"Heterogeneity of nephritic factor and its identification as an immunoglobulin","volume":"74","author":"Davis","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.116.1.1","article-title":"C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase","volume":"116","author":"Daha","year":"1976","journal-title":"J Immunol"},{"key":"B24","first-page":"449","article-title":"Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor","volume":"68","author":"Ito","year":"1989","journal-title":"Immunology"},{"key":"B25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-1759(01)00295-2","article-title":"A C3 convertase assay for nephritic factor functional activity","volume":"251","author":"Jelezarova","year":"2001","journal-title":"J Immunol Methods"},{"key":"B26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/CJN.07900811","article-title":"Causes of alternative pathway dysregulation in dense deposit disease","volume":"7","author":"Zhang","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/ndt\/9.7.811","article-title":"Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation","volume":"9","author":"Fremeaux-Bacchi","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int"},{"key":"B29","first-page":"73","article-title":"Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro","volume":"65","author":"Mollnes","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2249.1992.tb06984.x","article-title":"Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN)","volume":"89","author":"Ohi","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ki.2012.250","article-title":"Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation","volume":"82","author":"Paixao-Cavalcante","year":"2012","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","article-title":"Standardisation of the factor H autoantibody assay","volume":"219","author":"Watson","year":"2014","journal-title":"Immunobiology"},{"key":"B33","doi-asserted-by":"crossref","first-page":"19716","DOI":"10.1074\/jbc.270.34.19716","article-title":"Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis","volume":"270","author":"Hourcade","year":"1995","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1074\/jbc.M109322200","article-title":"Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb","volume":"277","author":"Hourcade","year":"2002","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"35725","DOI":"10.1074\/jbc.M111.263418","article-title":"Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein","volume":"286","author":"Hourcade","year":"2011","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.4049\/jimmunol.129.6.2603","article-title":"C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium","volume":"129","author":"Fishelson","year":"1982","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.4049\/jimmunol.1601121","article-title":"Interaction between multimeric von willebrand factor and complement: a fresh look to the pathophysiology of microvascular thrombosis","volume":"199","author":"Bettoni","year":"2017","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0090-1229(90)90144-F","article-title":"Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF","volume":"56","author":"Tanuma","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"B39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0090-1229(89)90141-4","article-title":"A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III","volume":"50","author":"Clardy","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"B40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0022-1759(90)90234-M","article-title":"Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis","volume":"131","author":"Ohi","year":"1990","journal-title":"J Immunol Methods"},{"key":"B41","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1073\/pnas.0810860106","article-title":"3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase","volume":"106","author":"Torreira","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.142.4.856","article-title":"Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase","volume":"142","author":"Fearon","year":"1975","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1084\/jem.144.4.1076","article-title":"Alternative pathway of complement: recruitment of precursor properdin by the labile C3\/C5 convertase and the potentiation of the pathway","volume":"144","author":"Medicus","year":"1976","journal-title":"J Exp Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fimmu.2012.00412","article-title":"Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement","volume":"3","author":"Cortes","year":"2012","journal-title":"Front Immunol"},{"key":"B45","first-page":"450","article-title":"C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase","volume":"65","author":"Ng","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.2215\/CJN.01820214","article-title":"Defining the complement biomarker profile of C3 glomerulopathy","volume":"9","author":"Zhang","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cei.12754","article-title":"Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy","volume":"184","author":"Corvillo","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/MNH.0000000000000412","article-title":"Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome","volume":"27","author":"Cook","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B49","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.imlet.2014.01.014","article-title":"Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome","volume":"160","author":"Jozsi","year":"2014","journal-title":"Immunol Lett"},{"key":"B50","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/ni.1755","article-title":"Structure of complement fragment C3b-factor H and implications for host protection by complement regulators","volume":"10","author":"Wu","year":"2009","journal-title":"Nat Immunol"},{"key":"B51","first-page":"33","article-title":"Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor","volume":"43","author":"Daha","year":"1981","journal-title":"Immunology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1093\/hmg\/ddp289","article-title":"The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity","volume":"18","author":"Tortajada","year":"2009","journal-title":"Hum Mol Genet"},{"key":"B53","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0162-3109(99)00005-3","article-title":"Decay acceleration of the complement alternative pathway C3 convertase","volume":"42","author":"Hourcade","year":"1999","journal-title":"Immunopharmacology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nsmb.2018","article-title":"Structural basis for engagement by complement factor H of C3b on a self surface","volume":"18","author":"Morgan","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"B55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4049\/jimmunol.122.1.75","article-title":"Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b","volume":"122","author":"Kazatchkine","year":"1979","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1055\/s-0034-1375299","article-title":"Treatment of C3 glomerulopathy with complement blockers","volume":"40","author":"Vivarelli","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMc1112273","article-title":"Eculizumab in a patient with dense-deposit disease","volume":"366","author":"Daina","year":"2012","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e96371","DOI":"10.1371\/journal.pone.0096371","article-title":"A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples","volume":"9","author":"Pauly","year":"2014","journal-title":"PLoS ONE"},{"key":"B60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2017","journal-title":"Nat Rev Nephrol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:56:44Z","timestamp":1775246204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2018.02329"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02329","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"article-number":"2329"}}